{
  "docId": "019de513-5f4b-73dc-86be-8541064db857",
  "docSlug": "39fb009494023464f8efb2a436e710b2",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 41 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 41,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes clinical trial data (PEACHTREE study) and market sizing context.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de513-5f4b-73dc-86be-8541064db857/18",
  "deckHref": "/decks/019de513-5f4b-73dc-86be-8541064db857",
  "deckJsonHref": "/decks/019de513-5f4b-73dc-86be-8541064db857.json",
  "deckAnchorHref": "/decks/019de513-5f4b-73dc-86be-8541064db857#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.35,
        "x": 0.04,
        "y": 0.72
      },
      "kind": "callout",
      "text": "2022 uveitis market in the U.S. is forecasted to be $433M – with ME associated with uveitis being a portion of that market",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "563a8e7c-b457-4b30-ace3-d5d76134579a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.4,
        "y": 0.48
      },
      "kind": "chart",
      "text": "PEACHTREE Study efficacy results: XIPERE vs Control",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9f887f7-1951-4058-b19b-7b90a98be2e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.2,
        "x": 0.76,
        "y": 0.17
      },
      "kind": "image",
      "text": "Anatomical diagram of the eye showing suprachoroidal space injection",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27ca9821-954c-44d7-8379-a49ce620204f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.04,
        "y": 0.48
      },
      "kind": "list",
      "text": "Developed in collaboration with Clearside Biomedical, Inc. Bausch + Lomb holds exclusive license for commercialization and development of XIPERE in the U.S. and Canada",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2bf968d-3ce1-4ab8-8a4d-17dacdd2e543",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.08,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "First and only therapy available in the U.S. that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, which is the leading cause of vision loss in people with uveitis",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb750b14-4710-49c8-a686-e6cc0f0fc42c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.15,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Massa, H., et al. (2019). 2. Best-corrected Visual Acuity (BCVA). 3. Macular edema. 4. 2021 Clarivate",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5bf7def2-f745-411d-b608-367854b413de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "XIPERE®: Approved by FDA and Launched Q1 2022",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fbfc235-6395-4377-aeb1-e6fa8952efc4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "1e4b80ea-6429-4743-97aa-c98f4041e647",
      "evidence": "The slide provides a concise overview of XIPERE, including its approval, launch, and market opportunity.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "4680255d-a1bb-4276-883c-44a14bf42472",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck highlights upcoming catalysts and pipeline opportunities",
      "position": 2,
      "confidence": 0.7,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 19,
      "from": 16,
      "beatId": "304b57bf-3b88-4260-82e0-48fa9015d63e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The deck showcases products and pipeline",
      "position": 4,
      "confidence": 0.7,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4b9c4e90-c116-437b-890e-c0c437c89a20",
      "evidence": "The deck highlights unmet market needs and pipeline opportunities",
      "position": 0,
      "objective": "What are the consequences of not addressing unmet market needs?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 19,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "71f350a9-5879-4044-b34e-c7e7d34cfdfe",
      "evidence": "The deck showcases new products and pipeline",
      "position": 1,
      "objective": "What are the potential benefits of investing in new products?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}